Saudi Press

Saudi Arabia and the world
Tuesday, Apr 21, 2026

Pfizer’s obscene $900m profit from its Covid vaccine in just three months proves capitalism and public health are bad bedfellows

Pfizer’s obscene $900m profit from its Covid vaccine in just three months proves capitalism and public health are bad bedfellows

The US pharmaceutical giant cashing in on a pandemic that has killed 3.2m people while failing to help the world’s poor is morally indefensible, and illustrates the corrupt nature of monopoly medicine.
As the New York Times reported, Pfizer generated hundreds of millions in profits in the first quarter of 2021, thanks to its successful Covid-19 vaccine. What’s interesting about the company’s success, however, is that its vaccine is one of just two widely used that are produced on a for-profit basis – and the only one whose manufacturer is not reliant on it to stay afloat. Pfizer’s windfall this year is, in essence, a windfall for monopoly medicine.

Unlike its Western competitors Johnson & Johnson and AstraZeneca, Pfizer decided early to profit from its vaccine. That profit margin hasn’t been disclosed, but it was predicted that this would be in the high 20% range. That means that, of the $3.5 billion brought in by the vaccine this quarter, about $900m is pre-tax profit.

Unlike Moderna, a competitor that uses similar vaccine technology to Pfizer’s, Pfizer is an extraordinarily profitable company already, making $9.6 billion in profits in 2020 before the vaccine had even had a serious impact. Moderna has no other products on the market, so turning a profit on its vaccine is crucial for its operation. Not so for Pfizer.

Pfizer sells its vaccine sales at different rates. The United States, for example, pays $19.50 for each dose, while Israel has reportedly paid $30.The reason all this is morally justifiable, Pfizer has said repeatedly, is that it was never part of the US government’s Operation Warp Speed and therefore should be allowed to set its own prices.

However, this is deceptive. BioNTech, the company that actually developed the vaccine, after which Pfizer basically slapped its label on it, received a $455 million grant from the German government and got around $6 billion in purchase commitments from the US and EU. Not only that, but the Pfizer vaccine is based on mRNA technology patented by the National Institutes of Health that was funded by US taxpayers.

In a nutshell, Pfizer capitalized on a partnership with a then-obscure German biotech company that received German government grants to develop its vaccine based on US taxpayer-funded technology, and then received purchasing guarantees from rich governments that guaranteed billions of dollars in revenue. It managed to privatize all the profits while socializing all the risk in what was a textbook case of how corrupt Big Pharma is.

But the scope of this monumental corruption really shines through when you consider that this is a once-in-several-lifetimes public health emergency that has killed millions of people. Governments around the world promised a warlike response to the Covid-19 pandemic and yet it’s mostly been just business as usual.

As I mentioned in my previous piece for RT on Bill Gates, global capitalism has reinforced itself through the pandemic, with Big Pharma being no exception. Intellectual property (IP) laws, which have only been defended in multilateral institutions such as the United Nations by rich countries, are demonstrably a barrier to getting vaccine doses out – and everyone knows it.

Even US President Joe Biden said on the campaign trail in 2020 that he would suspend IP rights to make vaccines more affordable around the globe.

“Absolutely, positively. This is the only humane thing in the world to do,” Biden said. (I’m sure the fact that Pfizer was among the companies that handed over a maximum $1 million donation to Biden’s inauguration had nothing to do with his about-face…)

But not only has IP been an issue, but even the general cost and logistics of transporting the Pfizer vaccine has proven a challenge for nations, especially poorer ones, that want to receive it. Yet, somehow, the Pfizer vaccine is emerging as the predominant Covid-19 vaccine shipped by Western countries, while lower-cost, less-intensive vaccines are being discredited.

Aside from the obvious fact that China’s vaccines or Russia’s Sputnik V are being refused for consideration, are being delayed for review by other countries, or are being conspiratorially attacked by Western media, there does seem to be some kind of bias in favor of Pfizer, even among Western vaccine-makers.

Consider that Oxford University published a study on April 15 showing that the risk of portal vein thrombosis (a blood clot in the liver) appears to be 30 times higher with the mRNA vaccines made by Moderna and Pfizer (that is, the two for-profit vaccines) than with AstraZeneca’s. Consider also that the risk of cerebral vein thrombosis (a blood clot in the brain) appears to be quite similar with both AstraZeneca (five in a million) and those mRNA vaccines (four in a million).

So, while blood-clotting concerns have caused controversy and even the discontinuation of vaccines made by AstraZeneca and Johnson & Johnson, any mention of this from mRNA vaccines in the media has been pretty much nonexistent. That’s quite strange.

Also, headlines trumpet all the time how highly effective Pfizer’s vaccine is, placing huge importance on the percentage of its effectiveness without adding context. As the Vox YouTube channel masterfully explained in a video posted in March, it’s extremely difficult to compare vaccines – especially as they’re being tested in different parts and at different times.

Pfizer’s chief executive promised to ensure that poorer countries “have the same access as the rest of the world” to its vaccine. But as of last month, wealthy nations had secured more than 87% of the more than 700 million doses of Covid-19 vaccines dispensed worldwide, while poorer countries had received only 0.2%, according to the World Health Organization.

Pfizer has pledged 40 million doses to Covax, the partnership aimed at supplying vaccines to poor countries. But, as the New York Times report points out, that’s less than 2% of the 2.5 billion doses it aims to produce this year.

Now, none of this is to say that Pfizer’s vaccine is not effective and you shouldn’t take it. I received the Pfizer vaccine and will get my second dose on Friday. The best vaccine is the one you have access to. But the problem is that Pfizer’s seems to be getting too much free exposure in the media, despite the fact it's expensive, difficult to transport, and held under IP protections, making it inaccessible to most people in the world right now.

Pfizer has successfully maneuvered our corrupt system to rake in record profits with virtually no risk at all. It’s sad to say, but this happens all the time. However, right now, it’s only artificially prolonging a once-in-a-century pandemic that, I think most of us can agree, is destroying our lives. Let Pfizer’s success this year be a historic reminder of why capitalism and public health are totally incompatible.
Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
News Roundup
Microsoft lost 2.5 millions users (French government) to Linux
Strategic Saudi-Bahrain Causeway Closed Amid Security Concerns as Trump Deadline Approaches
Saudi Arabia Keeps Red Sea Oil Exports Flowing Despite Regional Tensions
Pipeline Attack Cuts Significant Share of Saudi Arabia’s Oil Export Capacity
Saudi Business Leader Abudawood Appointed Chairman of Merit Incentives Group
TotalEnergies Confirms Damage at Saudi Refinery Following Security Incident
Saudi Arabia Launches Early Construction Phase for King Salman Stadium Project
Saudi Shift Away from Longstanding Dollar Oil Framework Gains Attention Amid Iran Conflict
Türkiye and Saudi Arabia Resolve Long-Running Transit Visa Dispute
Saudi Oil Capacity and Pipeline Flows Reduced as Supply Risks Intensify
TotalEnergies Reports Damage to Saudi SATORP Refinery Following Security Incidents
Gulf States Assess Prospects of U.S.-Iran Truce as Regional Stability Efforts Intensify
South Korea Resumes Honey Exports to Saudi Arabia Following Sanitary Approval
Saudi Arabia Carries Out Sentences in Eastern Province Following Security Convictions
Saudi Sovereign Wealth Fund Backs King Street’s Regional Credit Strategy
Saudi Arabia Secures World Cup Return as Egypt Celebrates Landmark Qualification
Iran and Saudi Arabia Intensify Diplomatic Engagement Amid Regional Tensions
Russia and Saudi Arabia Open Visa-Free Travel Corridor for Citizens
Saudi Oil Output Capacity Reduced by 600,000 Barrels Per Day Amid Regional Conflict
Saudi Arabia Suspends Operations at Select Energy Sites as Precautionary Measure
Saudi Arabia Halts Operations at Multiple Energy Facilities Amid Heightened Tensions
Global Markets Jolt as Iran Signals Ceasefire Breakdown and Rising Regional Tensions
King Street Aligns with Saudi Sovereign Wealth Fund to Expand Alternative Investments in Middle East
Attack on Saudi Arabia’s Jubail Petrochemical Hub Raises Global Supply Concerns
Debate Emerges Over Saudi Strategic Decisions as Gulf Cooperation Council Dynamics Come Into Focus
Saudi Arabia Expands Full Workforce Localisation to 69 Professions in Major Labour Reform
Emerging Alliance of Pakistan, Turkey, Egypt and Saudi Arabia Signals New Regional Power Dynamic Amid Iran Conflict
Iran Linked to Strikes Across Gulf States Following Refinery Attack Escalation
Saudi Arabia Voices Concern Over Fragile US–Iran Ceasefire Stability
Starmer Warns Sustained Effort Needed to Ensure US–Iran Ceasefire Holds
Saudi Arabia’s Key East-West Oil Pipeline Targeted Following Ceasefire Announcement
Iran Targets Saudi Arabia’s East-West Oil Pipeline in Escalating Regional Tensions
Trump Warns of Civilizational Stakes as Iran Halts Negotiations
Saudi Companies Expand Remote Work Measures Ahead of Iran-Related Security Concerns
Iran Warns of Strikes on Saudi Energy Infrastructure if US Targets Its Facilities
Iran Urges Civilians to Form Human Shields Around Nuclear Sites as Diplomatic Deadline Approaches
Saudi Arabia Raises Oil Prices to Record Premiums Amid Supply Pressures Linked to Iran Conflict
Key Saudi-Bahrain Causeway Closed Amid Heightened Security Concerns Linked to Iran
Formula One Calendar Gap Explained as Fans Await Next Grand Prix
Growing Strain on the Petrodollar System Comes Into Focus Amid Iran Conflict
Reported Strike on Saudi Arabia’s Jubail Complex Raises Global Energy Supply Concerns
FedEx Introduces New Digital Tool to Streamline Imports into Saudi Arabia
Iran Claims Strike on Saudi Arabia’s Jubail Petrochemical Complex Amid Rising Regional Tensions
Taiwan to Source Oil Shipments from Saudi Arabia’s Red Sea Ports
Saudi Arabia Evacuates Riyadh Financial District as Precaution Amid Regional Tensions
Saudi Arabia Balances Ambitious Economic Vision Amid Regional Tensions and Financial Pressures
Budget Saudi Arabia Reports Strong Full-Year 2025 Financial Performance
Saudi Arabia Expands Investment in Capcom With Stake Reaching Six Percent
Saudi Arabia Assesses Significant Economic Impact From Regional Conflict Involving Iran
×